NANOFORM FINLAND OYJ Insider information
Nanoform raises its mid-term business targets for 2025
- To nanoform annually at least 70 new active pharmaceutical ingredients, or `APIs' (40% increase from the previous target of at least 50 new APIs annually)
- To have in place 35 operating production lines, of which 7 to 14 are expected to be GMP compliant (40% increase from the previous target of 25 operating lines, of which 5-10 are GMP compliant)
- To have 200-250 employees (0-25% increase from the previous target of ~200)
- To have a gross margin over 90 percent (unchanged; re-iterated)
- To be cash flow positive (unchanged; re-iterated)
The raised midterm business targets are a consequence of several factors: the additional market opportunity foreseen for Nanoform's new biologics technology, the significant interest in Nanoform's service offering shown by the global pharma market, and the fact that both the number of companies developing novel drugs and the total number of APIs in the global pipeline continues to grow rapidly.
Since Nanoform's inception in 2015, the number of APIs in the global pharma pipeline has grown from 12,300 to more than 18,500 today*. During the last year alone, the number of APIs in the global pipeline has grown by almost 1,000*. Today there are more than 5,000 companies developing at least one active pharmaceutical ingredient, compared to 3,300 in 2015*. At the same time, the proportion of APIs with solubility and bioavailability problems remains high and today it is expected that 70%-90% of all new APIs in the pipeline have issues with solubility and bioavailability.
"During our first year as a dual-listed company on Nasdaq First North Premier Growth Market we have continued to see strong momentum in our business. The number of clients and projects have more than tripled while the number of employees and our line capacity has doubled. After launching our new technology platform for biologics, we can now also support partners within that market segment. We look with confidence to the future, working diligently towards meeting our new 2025 targets and answering to the needs of a growing patient population," said Prof. Edward Hæggström, CEO of Nanoform.
Nanoform will present the raised mid-term business targets for 2025 in detail at Nanoform's virtual Capital Markets Day on
*Source: Pharmaprojects® | Informa, 2021
The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on
For further information, please contact:
Albert Hæggström, CFO
albert.haeggstrom@nanoform.com / +358 29 370 0150
For investor relations queries, please contact:
hvh@nanoform.com / +46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks specified in Nanoform's prospectus published (on
https://news.cision.com/nanoform/r/nanoform-raises-its-mid-term-business-targets-for-2025,c3359632
https://mb.cision.com/Main/18905/3359632/1426780.pdf
(c) 2021 Cision. All rights reserved., source
